OraSure Technologies to Defend Patent Infringement Lawsuit

  
    
  
  
    
      OraSure Technologies, Inc. (NASDAQ:OSUR) announced that it has received 
      a complaint from Inverness Medical Innovations, Inc. (AMEX:IMA), 
      Inverness Medical Switzerland GmbH and Church & Dwight, Co., Inc. 
      (NYSE:CHD), filed in the United States District Court for the District 
      of New Jersey, alleging that the manufacture and sale of the Company’s 
      OraQuick ADVANCE® 
      Rapid HIV-1/2 Antibody Test infringes U.S. Patent No. 6,485,982. OraSure 
      Technologies believes that none of its products, including the OraQuick ADVANCE® 
      Test, infringe the patent or other intellectual property rights of any 
      party. The Company also believes that the asserted patent is invalid and 
      intends to defend this lawsuit vigorously.
    
    
      About OraSure Technologies
    
    
      OraSure Technologies develops, manufactures and markets oral fluid 
      specimen collection devices using proprietary oral fluid technologies, 
      diagnostic products including immunoassays and other in vitro 
      diagnostic tests, and other medical devices. These products are sold in 
      the United States as well as internationally to various clinical 
      laboratories, hospitals, clinics, community-based organizations and 
      other public health organizations, distributors, government agencies, 
      physicians’ offices, and commercial and 
      industrial entities.
    
    
      OraSure Technologies is the leading supplier of oral-fluid collection 
      devices and assays to the public health and life insurance markets for 
      the detection of antibodies to HIV. In addition, the Company supplies 
      oral-fluid testing solutions for drugs of abuse testing. For more 
      information on the Company, please go to www.orasure.com.